MTOR and neoplasm: At the same time, inhibitors of the PI3K/mTOR pathway investigated in preclinical studies as well as in clinical trials in GBM and other tumor types, show improved median survival, reduced local and metastatic growth, and tumor growth inhibition33,44–48.